Global Oncology/Cancer Drugs Market 2016 Trends, Analysis, Outlook, Shares, Forecasts and Study

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. 

Check complete report @

http://www.marketintelreports.com/report/allied0122/global-oncologycancer-drugs-market-therapeutic-modalities-cancer-types-and-geography–size-share-trends-company-profiles-demand-insights-analysis-research-report-opportunities-segmentation-and-forecast-2013–2020

 However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.Geographically, North America, dominates the market followed by Europe.

North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period.

Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. and GlaxoSmithKline. Companies operating in the cancer drugs market focus on several strategies such as collaboration, approval and acquisition.KEY BENEFITSThe report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize onThe report helps in understanding the strategies adopted by various companies for gaining market share in the cancer drugs marketThe report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs marketMarket conditions of cancer drugs market across all geographic regions are comprehensively analyzedCompetitive intelligence (of leading manufacturers) helps in understanding the competitive scenario across the geographiesSWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companiesMARKET SEGMENTATIONThe cancer drugs market is segmented by the therapeutic modalities, cancer types and geography.MARKET BY THERAPEUTIC MODALITIESChemotherapyTargeted TherapyImmunotherapy (Biologic Therapy)Hormonal TherapyOthersMARKET BY CANCER TYPESBlood CancerBreast CancerGastrointestinal CancerProstate CancerRespiratory/Lung CancerSkin CancerOther CancersMARKET BY GEOGRAPHYNorth AmericaUnited StatesCanadaMexicoEuropeGermanyFranceUnited KingdomOthersAsia-PacificIndiaChinaJapanAustraliaOthersLAMEAGCC (Gulf Corporation Council)Others

Order a copy of Report @  http://www.marketintelreports.com/purchase.php?id=allied0122

About us:

MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.

MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.

MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

Contact us:

Mayur S.
Sales Manager

2711 Centerville Road, Suite 400,
Wilmington,
Delaware,
19808United States
www.marketintelreports.com

[email protected]
Telephone: 1-302-261-5343